4D Molecular Therapeutics (NASDAQ:FDMT) Insider David Kirn Sells 42,608 Shares of Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider David Kirn sold 42,608 shares of 4D Molecular Therapeutics stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $12.87, for a total value of $548,364.96. Following the completion of the transaction, the insider owned 899,877 shares of the company’s stock, valued at approximately $11,581,416.99. This trade represents a 4.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

David Kirn also recently made the following trade(s):

• On Friday, July 10th, David Kirn sold 15,725 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $12.03, for a total value of $189,171.75.
• On Monday, June 22nd, David Kirn sold 114,746 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $10.47, for a total value of $1,201,390.62.
• On Monday, June 1st, David Kirn sold 1,922 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $10.02, for a total value of $19,258.44.

4D Molecular Therapeutics Stock Up 3.5%

FDMT stock opened at $11.70 on Wednesday. The firm has a market capitalization of $611.68 million, a PE ratio of -4.55 and a beta of 2.70. 4D Molecular Therapeutics, Inc. has a twelve month low of $4.11 and a twelve month high of $14.00. The stock has a 50-day simple moving average of $10.30 and a two-hundred day simple moving average of $9.39.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). 4D Molecular Therapeutics had a negative return on equity of 36.83% and a negative net margin of 182.34%.The firm had revenue of $3.05 million during the quarter, compared to analysts’ expectations of $2.59 million. On average, equities research analysts anticipate that 4D Molecular Therapeutics, Inc. will post -4.14 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have issued reports on FDMT. HC Wainwright reiterated a “buy” rating and issued a $36.00 target price on shares of 4D Molecular Therapeutics in a research note on Friday, March 20th. Wall Street Zen lowered shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Monday, April 20th. Royal Bank Of Canada increased their price objective on 4D Molecular Therapeutics from $32.00 to $35.00 and gave the stock an “outperform” rating in a research report on Thursday, March 19th. Finally, The Goldman Sachs Group set a $33.00 price objective on 4D Molecular Therapeutics in a research note on Friday, May 8th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, 4D Molecular Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $29.88.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Hedge funds have recently bought and sold shares of the stock. Wexford Capital LP purchased a new position in 4D Molecular Therapeutics in the 3rd quarter worth approximately $41,000. Daiwa Securities Group Inc. raised its position in shares of 4D Molecular Therapeutics by 3,362.0% during the 4th quarter. Daiwa Securities Group Inc. now owns 6,370 shares of the company’s stock valued at $48,000 after buying an additional 6,186 shares in the last quarter. Susquehanna Portfolio Strategies LLC bought a new stake in shares of 4D Molecular Therapeutics during the 4th quarter worth $77,000. Martingale Asset Management L P lifted its stake in 4D Molecular Therapeutics by 12.4% during the fourth quarter. Martingale Asset Management L P now owns 11,775 shares of the company’s stock worth $88,000 after purchasing an additional 1,303 shares during the last quarter. Finally, Gabelli Funds LLC purchased a new position in shares of 4D Molecular Therapeutics in the 4th quarter worth about $90,000. 99.27% of the stock is currently owned by institutional investors.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.